Background Coronavirus disease 2019 (COVID-19) not only caused a large surge of respiratory infections, it also had a potential association with and increases the risk of stroke. The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke (AIS); however, data regarding outcomes of intravenous tissue plasminogen activator (IV TPA) administration in stroke patients with COVID-19 remains limited. Case presentation Three AIS patients with confirmed COVID-19 treated using IV tPA. One case had excellent outcome, while the other cases showed unfavorable results. The risk–benefit ratio of IV TPA in COVID-19 remains unclear. Conclusion In this article, we discuss the possible explanation behind these different outcomes. Although IV tPA could not cure COVID-19, we suggest that its administration should not be delayed in AIS patients with COVID-19.
【저자키워드】 COVID-19, Case series, Ischemic Stroke, intravenous thrombolysis, Rt-PA, 【초록키워드】 respiratory infections, Coronavirus disease 2019, pandemic, stroke, risk, outcome, outcomes, management, Patient, association, administration, intravenous, tissue plasminogen activator, caused, provided, treated, increase, AIS, patients with COVID-19, 【제목키워드】 stroke, intravenous,